Skip to main content
. 2010 Nov;51(11):3166–3173. doi: 10.1194/jlr.M008334

TABLE 1.

DHA incorporation coefficients k* in iPLA2β+/+, iPLA2β+/−, and iPLA2β−/− mice in response to arecoline in regions with statistically significant genotype × drug interactions

iPLA2β+/+
 iPLA2β
 iPLA2β−1
Brain Region Saline (n = 7) Arecoline (n = 6) Saline (n = 7) Arecoline (n = 6) Saline (n = 8) Arecoline (n = 6)
Frontal cortex (10)
 Layer I 17.26 ± 2.43 43.59 ± 4.67*** 13.89 ± 2.10 26.92 ± 7.05*** 13.62 ± 2.77 35.49 ± 8.23***
 Layer IV 23.11 ± 2.15 56.32 ± 10.80*** 16.59 ± 3.05 26.02 ± 8.51* 15.50 ± 4.49 30.47 ± 7.53***
Frontal cortex (8)
 Layer I 20.24 ± 5.02 49.42 ± 10.44*** 16.68 ± 3.44 26.47 ± 7.99* 14.85 ± 4.03 26.37 ± 3.94**
 Layer IV 25.38 ± 4.42 56.43 ± 14.09*** 19.52 ± 5.08 31.01 ± 7.47* 16.18 ± 5.52 33.25 ± 6.98**
Pyriform cortex 13.32 ± 2.87 29.88 ± 6.53*** 14.83 ± 3.59 16.40 ± 2.63 11.22 ± 1.85 19.48 ± 4.48**
Anterior cingulate cortex 24.53 ± 5.83 53.01 ± 7.23*** 17.52 ± 3.42 25.33 ± 5.65* 16.18 ± 2.59 27.50 ± 6.13**
Motor cortex
 Layer I 17.10 ± 3.87 38.85 ± 7.91*** 13.85 ± 2.86 21.21 ± 5.13* 12.19 ± 2.50 21.68 ± 2.33**
 Layer II-III 18.79 ± 3.66 40.45 ± 8.95*** 15.38 ± 2.27 20.63 ± 3.58 12.35 ± 1.68 25.73 ± 4.12***
 Layer IV 23.87 ± 4.46 48.30 ± 6.71*** 17.38 ± 3.80 26.14 ± 7.79 15.15 ± 1.82 28.89 ± 5.91*
 Layer V 19.98 ± 3.76 41.87 ± 5.88*** 13.64 ± 2.41 19.28 ± 4.11* 12.40 ± 1.24 22.18 ± 4.26***
 Layer VI 18.48 ± 4.08 38.19 ± 6.83*** 13.77 ± 2.17 19.75 ± 4.73* 11.29 ± 1.32 22.70 ± 4.04***
Somatosensory cortex
 Layer I 20.69 ± 6.07 42.60 ± 4.62*** 13.95 ± 2.80 22.09 ± 3.47* 12.47 ± 1.69 24.15 ± 3.74***
 Layer II-III 21.28 ± 5.16 45.63 ± 5.77*** 16.33 ± 2.36 23.54 ± 4.83* 15.55 ± 2.86 27.34 ± 3.41***
 Layer IV 27.81 ± 5.45 56.28 ± 8.22*** 19.63 ± 3.83 27.27 ± 6.29* 18.66 ± 4.13 28.44 ± 3.95**
 Layer V 25.58 ± 4.51 51.77 ± 5.19*** 17.76 ± 2.84 24.84 ± 6.01* 16.84 ± 2.16 23.29 ± 4.47
 Layer VI 23.20 ± 2.97 47.85 ± 6.62*** 16.57 ± 2.47 24.21 ± 5.44* 14.26 ± 2.10 25.23 ± 6.72**
Auditory cortex
 Layer I 21.55 ± 3.99 41.05 ± 6.87*** 14.26 ± 4.04 22.85 ± 5.16** 14.32 ± 2.41 20.06 ± 4.79
 Layer IV 25.83 ± 4.16 45.68 ± 7.94*** 14.29 ± 3.47 23.23 ± 4.72** 16.79 ± 2.48 21.50 ± 4.22
Visual cortex
 Layer I 21.52 ± 2.44 42.42 ± 7.26*** 13.69 ± 4.21 24.62 ± 4.97*** 14.21 ± 2.48 21.55 ± 3.83*
 Layer IV 21.52 ± 2.70 49.95 ± 7.92*** 15.58 ± 5.00 29.33 ± 3.56*** 15.13 ± 3.15 23.94 ± 4.19
 Layer VI 23.25 ± 2.11 42.19 ± 5.80*** 12.36 ± 2.60 27.56 ± 3.62*** 13.58 ± 2.62 21.37 ± 3.48***
 Preoptic area (LPO/MPO) 16.01 ± 4.19 29.25 ± 3.46*** 13.36 ± 2.59 15.58 ± 2.32 12.32 ± 3.90 16.93 ± 3.50
 Olfactory tubercle 17.35 ± 2.68 45.28 ± 8.80*** 15.70 ± 2.79 21.55 ± 5.96 15.37 ± 5.04 25.84 ± 6.64**
 Diagonal band ventral 22.42 ± 2.66 45.49 ± 9.71*** 15.49 ± 5.01 23.52 ± 8.01 15.23 ± 3.38 18.99 ± 7.65
 Hippocampus
 Dentate gyrus 21.94 ± 2.09 39.16 ± 5.61*** 16.01 ± 5.91 20.62 ± 4.15 12.65 ± 2.21 21.55 ± 3.46**
SLM 28.44 ± 2.14 55.89 ± 10.30*** 17.13 ± 4.29 29.18 ± 5.07** 16.11 ± 2.39 28.24 ± 1.87**
 Caudate putamen
  Ventral 19.88 ± 3.80 41.69 ± 7.92*** 13.59 ± 1.54 23.51 ± 7.00** 13.40 ± 2.33 23.65 ± 5.18***
Lateral 19.45 ± 3.57 43.43 ± 8.07*** 13.94 ± 2.24 23.92 ± 6.57** 13.96 ± 2.59 22.35 ± 4.05**
Medial 18.90 ± 3.90 40.91 ± 9.06*** 14.49 ± 2.16 22.96 ± 7.14* 15.46 ± 2.46 24.04 ± 5.38*
Lateral geniculate nu 32.73 ± 3.36 62.51 ± 10.24*** 21.58 ± 4.13 37.16 ± 7.37** 19.52 ± 3.51 35.21 ± 9.86**
Thalamus
Ventroposterior lateral nu 28.88 ± 4.15 57.47 ± 9.48*** 23.45 ± 5.28 29.75 ± 6.26 17.64 ± 4.40 32.36 ± 8.89***
Paratenial nu 22.68 ± 5.37 42.71 ± 7.63*** 19.26 ± 2.55 24.25 ± 9.00 15.68 ± 3.29 27.59 ± 4.61**
Anteroventral nu 38.27 ± 9.31 74.67 ± 11.29*** 26.24 ± 5.36 36.71 ± 10.30 24.70 ± 3.76 37.03 ± 7.08*
Anteromedial nu 25.86 ± 5.52 51.43 ± 8.39*** 20.49 ± 3.97 26.37 ± 7.68 17.43 ± 3.46 35.35 ± 8.16***
Reticular nu 28.78 ± 5.54 53.21 ± 8.81*** 19.68 ± 2.61 28.50 ± 6.11 17.56 ± 2.85 33.54 ± 8.17***
Subthalamic nu 30.42 ± 3.72 70.68 ± 11.19*** 22.24 ± 3.45 28.39 ± 8.70 21.99 ± 5.11 26.72 ± 8.93
Hypothalamus
Supraoptic nu 16.65 ± 3.05 34.50 ± 4.42*** 13.26 ± 1.38 17.27 ± 4.17 13.52 ± 4.62 17.82 ± 1.91
Posterior 25.27 ± 4.77 46.65 ± 8.50*** 15.76 ± 4.08 22.96 ± 5.91 15.25 ± 3.47 24.84 ± 3.57**
Interpeduncular nu 39.44 ± 5.13 77.35 ± 9.91*** 27.20 ± 6.92 36.91 ± 8.63 25.77 ± 3.54 37.41 ± 10.28
Pretectal area 27.51 ± 4.22 59.79 ± 6.65*** 16.05 ± 3.86 26.97 ± 5.79** 16.30 ± 3.35 30.45 ± 4.30 **
Gray layer sup colliculus 24.72 ± 3.33 49.41 ± 6.45*** 15.68 ± 2.87 26.67 ± 7.10** 15.90 ± 2.04 26.81 ± 3.23***
Superior colliculus 24.80 ± 2.47 51.92 ± 11.22*** 21.09 ± 6.30 28.69 ± 6.71 15.82 ± 2.80 30.00 ± 5.34***
Inferior colliculus 43.06 ± 9.39 82.49 ± 13.77*** 26.60 ± 4.82 44.20 ± 8.36** 26.15 ± 6.91 38.30 ± 5.82**
Flocculus 30.51 ± 5.40 57.19 ± 7.23*** 20.05 ± 4.49 33.69 ± 4.76** 19.33 ± 4.60 29.28 ± 9.72*
Molecular layer cerebellar gray matter
33.28 ± 9.21 75.97 ± 5.55*** 25.69 ± 2.86 38.64 ± 6.09** 24.31 ± 4.84 37.70 ± 8.05*
Non-blood-brain barrier regions
Subfornical organ 20.66 ± 5.47 51.42 ± 12.90*** 14.22 ± 2.92 21.35 ± 6.14 15.42 ± 3.12 23.18 ± 5.19

Data are mean ± SD. k* = (ml/s/g) × 10−4. Mice were given methylatropine (4 mg/kg, subcutaneously) or saline 17 min before administration of saline or arecoline (30 mg/kg i.p.). [14C]DHA infusion was started 3 min after arecoline administration. In cases of statistically significant genotype × arecoline interactions, main effects are not reported, and Bonferroni's post tests were performed. *P < 0.05; **P < 0.01; ***P < 0.001; iPLA2β+/+ plus arecoline vs. iPLA2β+/+ saline; iPLA2β+/− plus arecoline vs. iPLA2β+/− saline, iPLA2β−/− plus arecoline vs. iPLA2β−/− saline. nu, nucleus; SLM, stratum lacunosum-moleculae of hippocampus.